Sangamo Therapeutics (SGMO) News Today $0.84 -0.03 (-3.54%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$0.84 +0.01 (+0.69%) As of 03/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Royal Bank of Canada Reaffirms "Sector Perform" Rating for Sangamo Therapeutics (NASDAQ:SGMO)March 20, 2025 | americanbankingnews.comTruist Financial Sticks to Its Buy Rating for Sangamo Biosciences (SGMO)March 19, 2025 | markets.businessinsider.comSangamo Therapeutics (NASDAQ:SGMO) Receives Sector Perform Rating from Royal Bank of CanadaRoyal Bank of Canada reiterated a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday.March 19, 2025 | marketbeat.comBrokerages Set Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Target Price at $5.80March 19, 2025 | americanbankingnews.com3SGMO : 8 Analysts Assess Sangamo Therapeutics: What You Need To KnowMarch 18, 2025 | benzinga.comSangamo Therapeutics (NASDAQ:SGMO) Announces Earnings Results, Misses Estimates By $0.02 EPSSangamo Therapeutics (NASDAQ:SGMO - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.March 18, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO) Posts Earnings ResultsSangamo Therapeutics (NASDAQ:SGMO - Get Free Report) posted its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.March 18, 2025 | marketbeat.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call TranscriptMarch 18, 2025 | msn.comRBC Capital Sticks to Their Hold Rating for Sangamo Biosciences (SGMO)March 18, 2025 | markets.businessinsider.comSangamo Biosciences (SGMO) Gets a Hold from Wells FargoMarch 18, 2025 | markets.businessinsider.comSangamo Therapeutics shares fall as Q4 results miss estimatesMarch 18, 2025 | investing.comSangamo reports Q4 EPS (11c) vs (34c) last yearMarch 18, 2025 | markets.businessinsider.comSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comSangamo options imply 29.8% move in share price post-earningsMarch 18, 2025 | markets.businessinsider.comSangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call TranscriptMarch 17, 2025 | seekingalpha.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from BrokeragesSangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the five research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating and four have issued a buy ratinMarch 16, 2025 | marketbeat.comSangamo Therapeutics (SGMO) Expected to Announce Earnings on MondaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=673373)March 15, 2025 | marketbeat.comSangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO)Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 23,134 call options on the company. This represents an increase of approximately 432% compared to the average volume of 4,347 call options.March 13, 2025 | marketbeat.comDianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue EstimatesMarch 11, 2025 | msn.comSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor ConferenceMarch 6, 2025 | businesswire.comSangamo Therapeutics (SGMO) Projected to Post Earnings on WednesdaySangamo Therapeutics (NASDAQ:SGMO) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comSangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89%March 1, 2025 | uk.finance.yahoo.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendationFebruary 19, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for Sangamo Biosciences (SGMO)February 7, 2025 | markets.businessinsider.comSangamo announces updated data from STAAR studyFebruary 6, 2025 | markets.businessinsider.comSangamo reports positive Fabry disease gene therapy resultsFebruary 6, 2025 | msn.comSangamo reports updated data for gene therapy candidate ST-920February 6, 2025 | msn.comSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety ProfileFebruary 6, 2025 | businesswire.comGolden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)Golden State Equity Partners lifted its holdings in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 2,592.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 325,684 shares of the biopharmaceutical company's stock aftFebruary 4, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for SGMO FY2024 Earnings?Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright cut their FY2024 earnings per share estimates for Sangamo Therapeutics in a report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings of ($0.49)January 30, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOJanuary 28, 2025 | prnewswire.comSangamo Therapeutics (NASDAQ:SGMO) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday.January 28, 2025 | marketbeat.comSangamo Biosciences Receives ‘Buy’ Rating from Patrick Trucchio Amid Anticipated Collaborations and Gene Therapy AdvancesJanuary 27, 2025 | markets.businessinsider.comExpert Outlook: Sangamo Therapeutics Through The Eyes Of 11 AnalystsJanuary 27, 2025 | benzinga.comSangamo Therapeutics (NASDAQ:SGMO) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Sangamo Therapeutics in a report on Monday.January 27, 2025 | marketbeat.comSangamo price target lowered to $5 from $7 at TruistJanuary 24, 2025 | markets.businessinsider.comTruist Financial Keeps Their Buy Rating on Sangamo Biosciences (SGMO)January 23, 2025 | markets.businessinsider.comTruist Financial Lowers Sangamo Therapeutics (NASDAQ:SGMO) Price Target to $5.00Truist Financial cut their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a report on Thursday.January 23, 2025 | marketbeat.comSangamo Biosciences Holds Steady Amid Partnership Prospects and Program UncertaintiesJanuary 18, 2025 | markets.businessinsider.comSangamo Therapeutics Inc. (SGMO): This Small-Cap Stock Is Poised To Outperform in 2025January 7, 2025 | msn.comPFE Returns Rights to Hemophilia A Candidate to Partner SGMOJanuary 3, 2025 | finance.yahoo.comSecurities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities ...January 3, 2025 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sangamo Therapeutics, Inc. - SGMOJanuary 2, 2025 | prnewswire.comSangamo Therapeutics, Inc. (SGMO) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud InvestigationJanuary 2, 2025 | businesswire.comSecurities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmJanuary 2, 2025 | businesswire.comSecurities Fraud Investigation Into Sangamo Therapeutics, Inc. (SGMO) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. CruzJanuary 2, 2025 | businesswire.comSangamo Therapeutics (NASDAQ:SGMO) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Thursday.January 2, 2025 | marketbeat.comSangamo Biosciences: Overcoming Setbacks with Strategic Partnerships and Fabry Program PotentialJanuary 1, 2025 | markets.businessinsider.com9 Analysts Have This To Say About Sangamo TherapeuticsJanuary 1, 2025 | benzinga.comSangamo Therapeutics: Left At The Alter (Rating Downgrade)January 1, 2025 | seekingalpha.com Remove Ads Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address SGMO Media Mentions By Week SGMO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SGMO News Sentiment▼0.020.77▲Average Medical News Sentiment SGMO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SGMO Articles This Week▼53▲SGMO Articles Average Week Remove Ads Get Sangamo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RIGL News EBS News VSTM News VNDA News CDXS News XOMA News IRWD News ACHV News RGLS News LXRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SGMO) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sangamo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sangamo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
